49 results
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
autoleucel Discontinued n (%) 26 (17) Death 15 (10) Manufacturing-related 7 (5) Adverse event 2 (1) Physician decision 1 (0.7) Progressive disease 1
8-K
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
earlier death, resignation or removal.
Mr. Bonney, age 65, possesses over 30 years of operational, commercial and senior management experience … and qualified, or until his earlier death, resignation or removal.
Dr. Rao, age 55, has served as Chief Medical Officer of Sitryx, a biopharmaceutical company
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
of the programmed T cell and triggers cell death. We use the RQR8 safety switch in our AUTO4, AUTO5 and AUTO6NG programs.
Rapamycin Safety Switch (RapaCasp9 … rapamycin. Once administered, rapamycin heterodimerises caspase 9 via FRB and FKBP to activate a cell death cascade and selectively eliminate
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
high risk of infection. In fact, many of these patients do pass away as a consequence of sepsis in general as a major cause of death. And as you can
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
disposition Developing Next Generation Programmed T Cell Therapies 11 127/153 (83%) enrolled patients received obe-cel* Discontinued n (%) 26 (17) Death 15 (10
8-K
EX-99.1
u7glz
13 Feb 24
Regulation FD Disclosure
4:06pm
8-K
vrjykcms
10 Jan 24
Departure of Directors or Certain Officers
3:12pm
8-K
w7d oe6q5
22 Dec 23
Departure of Directors or Certain Officers
8:24am
8-K
EX-99.1
6oplmj
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.2
5ygl36v
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
EX-10.1
ya18ax4y3rpagn86cdmd
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
om559aduvgm9
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
a80na 04g9kx1q
20 Jun 23
Current report (foreign)
4:59pm
6-K
EX-99.3
pbbffnzxfi8ugc
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-1
m9g2vksz
1 Jul 22
Current report (foreign)
5:15pm
6-K
tegegqdjncr1hqs1wzbi
15 Nov 21
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
12:00am
6-K
vyv1eu4j2fhl
15 Sep 21
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
4:30pm
6-K
EX-1
u760t3 ttkydw
30 Jun 21
Annual Report and Accounts
6:05am